Nebraska exosomes

FDA needs to act boldly on unproven exosome therapies

exosomes-visualized-by-EM

The FDA needs to do more about clinics and suppliers of unproven “exosome therapies.” Dubious exosomes are sadly just the newest gimmick for some firms in the stem cell/regenerative medicine clinic arena right now. They are available at many stem cell and other clinics right now, but who knows what’s in the syringe? Also, people …

FDA needs to act boldly on unproven exosome therapies Read More »

B+ on my report card on my 20 stem cell predictions for 2019

stem-cell-crystal-ball-predictions-1

Last year around this time I took my annual plunge to make 20 predictions for the coming year for the stem cell and regenerative medicine field. I even made a crystal ball graphic to highlight the complexity of the stem cell ecosystem into which these predictions were embedded (see image) for 2019. How’d I do? …

B+ on my report card on my 20 stem cell predictions for 2019 Read More »

FDA spike: clinic supplier Liveyon warning letter & 483s; notice on exosome harms

Roya-Panah-Kosolcharoen

Friday and Saturday showed a burst in FDA activity related to unproven stem cells and regenerative products including a warning letter to the unproven perinatal “stem cell” provider Liveyon. This was an unusual 48-hour period and a very good one for those who believe in science-based regenerative medicine but in my view a bad day …

FDA spike: clinic supplier Liveyon warning letter & 483s; notice on exosome harms Read More »